Moleti Mariacarla, Sturniolo Giacomo, Di Mauro Maria, Russo Marco, Vermiglio Francesco
Unit of Endocrinology, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Front Endocrinol (Lausanne). 2017 May 23;8:111. doi: 10.3389/fendo.2017.00111. eCollection 2017.
Differentiated thyroid cancer (DTC) is markedly more common in women than men, the highest female-to-male ratio being recorded during the reproductive period. This evidence has led to the suggestion that female hormonal and reproductive factors may account for the observed DTC gender disparity. This review focuses on current evidence on the risk of DTC in conjunction with major female reproductive factors, including the impact of pregnancy on DTC occurrence and progression/recurrence. Overall, studies exploring the link between the risk of DTC and menstrual and menopausal factors, oral contraceptives and/or hormone replacement therapy, showed these associations, if any, to be generally weak. Nonetheless, there is some evidence that higher levels of exposure to estrogens during reproductive years may confer an increased risk of DTC. As far as pregnancy is concerned, it is unclear whether a potential association between parity and risk of DTC actually exists, and whether it is enhanced in the short-term following delivery. A possible role for pregnancy-related factors in DTC progression has been recently suggested by some reports, the results of which are consistent with a worse outcome in the short-term of women diagnosed with DTC during gestation compared to non-pregnant control patients. Also, some progression of disease has been described in women with structural evidence of disease prior to pregnancy. However, there seems to be no impact from pregnancy in DTC-related death or overall survival. Several and animal studies have evaluated the influence of estrogens (E) and estrogen receptors (ERs) on thyroid cell proliferation. Presently available data are indicative of a role of E and ERs in thyroid cancer growth, although considerable discrepancies in respect to ER expression patterns in thyroid cancer tissues actually exist. Further studies providing more direct evidence on the possible role of E and of placental hormones and growth factors on thyroid growth may expand our knowledge on the mechanisms beyond the gender disparity of proliferative thyroid diseases.
分化型甲状腺癌(DTC)在女性中比男性明显更为常见,在生育期记录到的女性与男性比例最高。这一证据表明,女性激素和生殖因素可能是观察到的DTC性别差异的原因。本综述重点关注与主要女性生殖因素相关的DTC风险的现有证据,包括妊娠对DTC发生、进展/复发的影响。总体而言,探索DTC风险与月经和绝经因素、口服避孕药和/或激素替代疗法之间联系的研究表明,这些关联(如果存在的话)通常较弱。尽管如此,有一些证据表明,生育年限内较高水平的雌激素暴露可能会增加DTC的风险。就妊娠而言,尚不清楚产次与DTC风险之间是否实际存在潜在关联,以及在分娩后的短期内这种关联是否会增强。最近一些报告提出了妊娠相关因素在DTC进展中的可能作用,其结果与妊娠期诊断为DTC的女性与非妊娠对照患者相比在短期内预后较差一致。此外,在妊娠前有疾病结构证据的女性中也描述了一些疾病进展情况。然而,妊娠似乎对DTC相关死亡或总体生存没有影响。多项体外和动物研究评估了雌激素(E)和雌激素受体(ERs)对甲状腺细胞增殖的影响。目前可得的数据表明E和ERs在甲状腺癌生长中起作用,尽管甲状腺癌组织中ER表达模式实际存在相当大的差异。关于E以及胎盘激素和生长因子对甲状腺生长可能作用的进一步研究,可能会扩展我们对增殖性甲状腺疾病性别差异背后机制的认识。